Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

164.79USD
25 Jun 2019
Change (% chg)

$35.22 (+27.18%)
Prev Close
$129.57
Open
$168.05
Day's High
$168.25
Day's Low
$164.28
Volume
1,100,100
Avg. Vol
582,235
52-wk High
$197.00
52-wk Low
$114.27

Select another date:

Deals of the day-Mergers and acquisitions

June 25 The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Tuesday:

AbbVie nears deal to buy Allergan for more than $60 bln - WSJ

June 25 AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than $60 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

UPDATE 1-Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

REFILE-UPDATE 1-Allergan's Vraylar wins U.S. FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

Allergan's Vraylar wins FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, making it a treatment option for a full spectrum of the condition's cyclical symptoms, the company said on Monday.

Allergan CEO says company is urgently looking at all options to boost share price

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Select another date: